KALA BIO, INC. Comprehensive Income
KALA BIO, INC. (KALA) reported Comprehensive Income of -$1.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-19
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$1.58M.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$1.62M.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $686.00K.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$7.56M.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$26.98M.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$38.51M.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$42.20M.
- KALA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$44.82M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.58M 10-Q · filed 2026-08-19 | -$3.20M 10-Q · filed 2026-08-19 | -$2.52M derived: sum of 3 quarters · filed 2026-08-19 | -$10.08M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$1.62M 10-Q · filed 2026-05-15 | -$935.00K derived: sum of 2 quarters · filed 2026-05-15 | -$8.50M derived: sum of 3 quarters · filed 2026-05-15 | -$19.65M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $686.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$6.88M derived: sum of 2 quarters · filed 2026-04-15 | -$18.03M derived: sum of 3 quarters · filed 2026-08-19 | -$26.98M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$7.56M 10-Q · filed 2025-11-19 | -$18.72M derived: sum of 2 quarters · filed 2026-08-19 | -$27.67M 10-Q · filed 2025-11-19 | -$35.84M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$11.15M 10-Q · filed 2026-08-19 | -$20.10M 10-Q · filed 2026-08-19 | -$28.28M derived: sum of 3 quarters · filed 2026-08-19 | -$37.23M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$8.95M 10-Q · filed 2026-05-15 | -$17.12M derived: sum of 2 quarters · filed 2026-05-15 | -$26.07M derived: sum of 3 quarters · filed 2026-05-15 | -$35.65M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$17.13M derived: sum of 2 quarters · filed 2026-04-15 | -$26.70M derived: sum of 3 quarters · filed 2026-04-15 | -$38.51M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$8.95M 10-Q · filed 2025-11-19 | -$18.53M derived: sum of 2 quarters · filed 2025-11-19 | -$30.34M 10-Q · filed 2025-11-19 | -$38.96M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | -$9.58M 10-Q · filed 2025-08-08 | -$21.39M 10-Q · filed 2025-08-08 | -$30.01M derived: sum of 3 quarters · filed 2025-08-08 | -$38.73M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$11.81M 10-Q · filed 2025-05-14 | -$20.43M derived: sum of 2 quarters · filed 2025-05-14 | -$29.15M derived: sum of 3 quarters · filed 2025-05-14 | -$39.55M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$8.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$17.34M derived: sum of 2 quarters · filed 2025-03-31 | -$27.74M derived: sum of 3 quarters · filed 2025-03-31 | -$42.20M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$8.71M 10-Q · filed 2024-11-12 | -$19.12M derived: sum of 2 quarters · filed 2024-11-12 | -$33.57M 10-Q · filed 2024-11-12 | -$46.41M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$10.40M 10-Q · filed 2024-08-06 | -$24.86M 10-Q · filed 2024-08-06 | -$37.70M derived: sum of 3 quarters · filed 2024-08-06 | -$8.63M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$14.46M 10-Q · filed 2024-05-14 | -$27.30M derived: sum of 2 quarters · filed 2024-05-14 | $1.78M derived: sum of 3 quarters · filed 2024-05-14 | -$26.33M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$12.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $16.23M derived: sum of 2 quarters · filed 2024-03-29 | -$11.88M derived: sum of 3 quarters · filed 2024-03-29 | -$44.82M 10-K · filed 2024-03-29 |
| 2022-09-30 | $29.07M 10-Q · filed 2023-11-13 | $964.00K derived: sum of 2 quarters · filed 2023-11-13 | -$31.98M 10-Q · filed 2023-11-13 | -$79.55M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$28.11M 10-Q · filed 2023-08-04 | -$61.05M 10-Q · filed 2023-08-04 | -$108.62M derived: sum of 3 quarters · filed 2023-08-04 | -$136.75M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | -$32.94M 10-Q · filed 2023-05-09 | -$80.51M derived: sum of 2 quarters · filed 2023-05-09 | -$108.64M derived: sum of 3 quarters · filed 2023-05-09 | -$145.14M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$47.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$75.69M derived: sum of 2 quarters · filed 2023-03-03 | -$112.20M derived: sum of 3 quarters · filed 2023-03-03 | -$142.61M 10-K · filed 2023-03-03 |
| 2021-09-30 | -$28.13M 10-Q · filed 2022-11-08 | -$64.63M derived: sum of 2 quarters · filed 2022-11-08 | -$95.04M 10-Q · filed 2022-11-08 | -$126.15M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$36.50M 10-Q · filed 2022-08-11 | -$66.91M 10-Q · filed 2022-08-11 | -$98.02M derived: sum of 3 quarters · filed 2022-08-11 | -$125.95M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$30.41M 10-Q · filed 2022-05-16 | -$61.52M derived: sum of 2 quarters · filed 2022-05-16 | -$89.45M derived: sum of 3 quarters · filed 2022-05-16 | -$112.75M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$31.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$59.04M derived: sum of 2 quarters · filed 2022-03-29 | -$82.33M derived: sum of 3 quarters · filed 2022-03-29 | -$104.32M 10-K · filed 2022-03-29 |
| 2020-09-30 | -$27.93M 10-Q · filed 2021-11-15 | -$51.23M derived: sum of 2 quarters · filed 2021-11-15 | -$73.22M 10-Q · filed 2021-11-15 | -$95.14M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$23.30M 10-Q · filed 2021-08-05 | -$45.25M 10-Q · filed 2021-08-05 | -$67.21M derived: sum of 3 quarters · filed 2021-08-05 | -$90.38M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$21.95M 10-Q · filed 2021-05-05 | -$43.91M derived: sum of 2 quarters · filed 2021-05-05 | -$67.09M derived: sum of 3 quarters · filed 2021-05-05 | -$90.91M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$21.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$45.13M derived: sum of 2 quarters · filed 2021-02-25 | -$68.96M derived: sum of 3 quarters · filed 2021-02-25 | -$94.35M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$23.18M 10-Q · filed 2020-11-05 | -$47.00M derived: sum of 2 quarters · filed 2020-11-05 | -$72.39M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$23.82M 10-Q · filed 2020-08-06 | -$49.21M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |